Next week, CEO Joanne Kotz, PhD, will deliver a corporate presentation at the RBC Capital Markets Global Healthcare Conference on Tues, 5/14 at 2:05pm ET. More here: bit.ly/3JTgiam #healthcare

Our team members recently spent a day volunteering together at The Greater Boston Food Bank. Currently, 1 in 3 Massachusetts residents face hunger, and we’re grateful for the opportunity to help make a difference in our community. #EndHungerHere

At the Society for Inherited Metabolic Diseases Annual Meeting next week, Jnana will present two posters on our SLC6A19 inhibitor program, including JNT-517, our first-in-class oral treatment in development for phenylketonuria ( #PKU ). SIMD bit.ly/3Q1ikJ4

CMO George Vratsanos, MD, will participate in a panel on “Innovation & Improvement: Bringing Forward the Next Wave of I&I Therapeutics” at the Goldman Sachs Healthruption: 3rd Annual Healthcare Disruption Conference on April 9. #immunology #biotech

Heading to the American Chemical Society’s Spring 2024 Meeting? Don’t miss our oral presentation describing how RAPID, our next-gen chemoproteomics platform, enables the discovery of small molecule medicines for challenging-to-drug targets. bit.ly/3TkDpii #ACSSpring2024 #medchem

It’s Rare Disease Day, which raises awareness for the 300 million people living with a rare disease around the world.

Our lead program is a potential 1st-in-class oral treatment for #PKU , a rare inherited metabolic disorder. Learn more: bit.ly/3TcX1WN
#rarediseaseday

CEO Joanne Kotz, PhD., CMO George Vratsanos, MD., and CFO Doug Pagán will participate in 1:1 meetings at the TD Cowen 44th Annual Health Care Conference and Leerink Partners Global Biopharma Conference. bit.ly/3SXjbLk

Will we see you there? #biotech #drugdiscovery

Check out the Endpoints News exclusive by Ryan Cross the Science Boss on positive interim results from our clinical study of JNT-517 in PKU.

Joanne Kotz, CEO, & George Vratsanos, CMO, discuss how the drug works, the significant unmet need in PKU & path to a pivotal trial. bit.ly/3vXBXKL

Each year, Jnana recognizes our team members who have gone above & beyond. We’re excited to share the recipients of our 2023 awards.
John Malona
Lara Gechijian
Kevin O’Rourke
Ted English
Andreu Viader
Roo St. Pierre
Alex Fitz
Hyejin Park
[L to R, back row 1st]
#biotech #culture

CEO Joanne Kotz, PhD, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Mon, Jan 8th at 5:30 pm PT. #JPM24 #biotech

The hit at this year’s holiday festivities? Jnanapoly, created by Matt Labenski.

We’re looking forward to the downtime next week during our company shutdown before proceeding to “GO” on the exciting advancements in store for Jnana in 2024.

#biotech #innovation

Jnana will wrap up a busy season of IR conferences with a virtual fireside chat on Dec 13 at the RBC Capital Markets Healthcare Private Company Conference. Company leadership will also participate in 1:1 meetings. bit.ly/3GvMUoN

#biotech #drugdiscovery

Dec. 3rd is National PKU Awareness Day, which raises awareness of the rare genetic disease phenylketonuria.

Our lead program is a potential first-in-class oral treatment for #PKU in a Phase 1b clinical trial. More here: ow.ly/eRbw50Qel86

#raredisease #clinicaltrials

Jnana CEO Joanne Kotz, Ph.D., will present a company overview at the 35th Annual Piper Sandler Healthcare Conference tomorrow at 9:50 am ET. ow.ly/66aA50QbAnn

#biotech #drugdiscovery

We’re thankful for our amazing team, their passion for our work, and getting to spend time together outside of the lab/office this fall. #biotech #culture

We couldn’t agree more that it’s an exciting time for small-molecule #drugdiscovery . Joel Barrish, co-founder of Jnana and now a venture partner at RA Capital, shares how advancements in chemistry and technology are allowing access to targets and biology not previously possible.

This week, members of our leadership team will be participating in 1:1 meetings at Leerink Partners Biopharma Private Company Connect and the Bank of America Healthcare Trailblazers Private Company Conference.

#biotechnology #biopharma